, and stenting over no stenting [3] , prospective, randomized human studies are unfortunately lacking.
Recently pancreaticogastrostomy has gained favor as a potential means of reducing the incidence of pancreatic fistula following the Whipple procedure [8] [9] [10] . A prospective, randomized trial from Johns Hopkins enrolled 145 patients and found no differences in the pancreatic fistula rates when comparing between pancreaticojejunostomy and pancreaticogastrostomy [11] . Of note, a multivariate logistic regression analysis performed as part of this prospective, randomized study revealed that the two factors most highly associated with pancreatic fistula were lower surgical volume, and either ampullary or duodenal disease in the resected pathology specimen. Importantly, there appeared to be a linear relationship between the number of cases performed during the study period by each surgeon, and the pancreatic leak rate, with those surgeons performing the greatest number of pancreatic-enteric anastomoses having the lowest leak rate. This underscores the. importance of the adage "Practice makes perfect" and would suggest that an experienced pancreatic surgeon may be expected to have the lowest pancreatic fistula rates independent of the method of pancreatic-enteric reconstruction.
A pharmacologic approach designed to reduce the rate of pancreatic fistula involves the perioperative inhibition of pancreatic exocrine secretion. To date, four randomized controlled multicenter trials have evaluated the use of prophylactic octreotide in patients undergoing pancreatic resection [12] [13] [14] [15] 
